New imaging method may spot tumor growth earlier after freezing treatment
NCT ID NCT06224283
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a detailed MRI analysis called radiomics can predict if a desmoid tumor will grow back after cryoablation (freezing treatment) better than standard methods. Researchers will follow 21 patients treated at one hospital to compare radiomics with usual size-based criteria. The goal is to catch signs of progression earlier, which could guide future care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cryoablation
- What this could lead to
- If successful, this could lead to a better way to predict tumor progression early, helping doctors decide on treatment sooner.
- What could go wrong
- This is a small, early study with only 21 participants, so results may not apply to everyone. The focus is on improving prediction, not on a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 21 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who were treated with cryoablation for desmoid tumor
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * desmoid tumor treated at Rizzoli Orthopaedic Institute with cryoablation * baseline MRI * clinical and radiologic follow-up until disease progression or the start of a new line of treatment performed every 3 months, with a minimum of 6 months follow-up Exclusion Criteria: \- not meeting inclusion criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Desmoid are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Giancarlo Facchini
RECRUITINGBologna, 40136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare tumor patients: chemo delivered directly to desmoid growths
- New hope for rare tumor patients: AL102 drug trial launches
- Can a Stress-Management program help young cancer patients cope?
- New Tamoxifen-Like drug tested for stubborn hormone cancers
- New drug FOG-001 takes on Hard-to-Treat cancers